Genmab stock gains as petosemtamab Phase 3 start and strong Q2 figures support valuation

Genmab A/S stock (ISIN DK0010272202) closed at 2,260.00 Danish kroner on the OMX Copenhagen exchange on September 18, 2026, up 0.71 percent or 16.00 points and at a new 52-week high according to Investing.com.

Phase 3 petosemtamab trial adds clinical momentum

As BioSniper reports, Genmab has started a Phase 3 colorectal cancer trial of its antibody petosemtamab with chemotherapy in RAS/BRAF wild-type second-line disease, with the study registered as starting on September 15, 2026.

The trial compares petosemtamab plus chemotherapy against treatment arms using cetuximab or bevacizumab, positioning Genmab to test whether its asset can improve outcomes over established regimens in this molecularly defined colorectal cancer segment according to BioSniper.

For investors, this Phase 3 start is a meaningful catalyst because it moves petosemtamab further along the development path and, if successful, could open a new commercial indication in colorectal cancer where targeted biologics are already widely used.

Q2 2026 results show double-digit growth and strong margins

The recent share strength is underpinned by robust second-quarter figures: in Q2 fiscal 2026, Genmab reported revenue of 7.49 billion Danish kroner and profit of 1.97 billion kroner, translating into a profit margin of 26.23 percent, according to IT-Boltwise.

According to IT-Boltwise, Genmab also exceeded a cited earnings expectation metric of 23.6 by delivering a result of 34.85 on this measure in Q2 fiscal 2026, beating the estimate by 11.25 units and underscoring the quarter as an earnings beat versus consensus.

This combination of high-20s profit margin and earnings outperformance versus expectations in Q2 2026 supports the narrative that Genmab is converting its oncology and immunology portfolio into profitable growth while investing in late-stage programs such as petosemtamab.

ADR price action and valuation context in US trading

Genmab is also traded in the United States via American Depositary Receipts (ADRs) under the ticker GMAB, where the ADRs closed at 34.40 United States dollars on September 16, 2026, as cited by IT-Boltwise.

According to IT-Boltwise, an analyst house has maintained a price target of 40.00 dollars for the ADRs and raised its Q3 earnings estimate around September 17, 2026, leaving the target roughly 16 percent above the 34.40 dollar close on September 16, 2026.

The 16 percent gap between the ADR closing level and the USD 40.00 target provides investors with a quantified sense of upside implied by this analyst view, while the margin of outperformance against Q2 expectations offers a fundamental basis for this stance.

Home-market valuation and fair value comparisons

Genmab’s Copenhagen listing has also drawn valuation discussions: the shares recently closed at 2,244 Danish kroner, while one intrinsic value estimate pegs fair value at 2,454 kroner, suggesting the stock could be around 9 percent undervalued relative to this model according to Simply Wall St.

In practical terms, the difference between the DKK 2,244 share price and the DKK 2,454 fair value estimate amounts to 210 kroner per share, quantifying the valuation gap discussed by this model-driven analysis from Simply Wall St.

The fact that Genmab’s stock is now trading at a 52-week high of 2,260.00 kroner on September 18, 2026, while still sitting below that cited fair value metric, highlights how recent price gains have narrowed but not fully closed the valuation gap identified by some model-based approaches.

Stock stays near its new 52-week high

Per Investing.com, Genmab stock ended the trading session on September 18, 2026 at 2,260.00 kroner on OMX Copenhagen, up 0.71 percent on the day and marking a fresh 52-week high.

More news and analyses on Genmab stock